Literature DB >> 18996872

Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition.

Francesca L Crowe1, Naomi E Allen, Paul N Appleby, Kim Overvad, Inge V Aardestrup, Nina F Johnsen, Anne Tjønneland, Jakob Linseisen, Rudolf Kaaks, Heiner Boeing, Janine Kröger, Antonia Trichopoulou, Assimina Zavitsanou, Dimitrios Trichopoulos, Carlotta Sacerdote, Domenico Palli, Rosario Tumino, Claudia Agnoli, Lambertus A Kiemeney, H Bas Bueno-de-Mesquita, María-Dolores Chirlaque, Eva Ardanaz, Nerea Larrañaga, José R Quirós, Maria-José Sánchez, Carlos A González, Pär Stattin, Göran Hallmans, Sheila Bingham, Kay-Tee Khaw, Sabina Rinaldi, Nadia Slimani, Mazda Jenab, Elio Riboli, Timothy J Key.   

Abstract

BACKGROUND: Plausible biological mechanisms underlie possible associations between fatty acids in blood and risk of prostate cancer; epidemiologic evidence for an association, however, is inconsistent.
OBJECTIVE: The objectives were to assess the association between plasma phospholipid fatty acids and risk of total prostate cancer by stage and grade.
DESIGN: This was a nested case-control analysis of 962 men with a diagnosis of prostate cancer after a median follow-up time of 4.2 y and 1061 matched controls who were taking part in the European Prospective Investigation into Cancer and Nutrition. The fatty acid composition of plasma phospholipids was measured by gas chromatography, and the risk of prostate cancer was estimated by using conditional logistic regression with adjustment for lifestyle variables.
RESULTS: We found a positive association between palmitic acid and risk of total, localized, and low-grade prostate cancer. The risk of prostate cancer for men in the highest quintile compared with the lowest quintile of palmitic acid was 1.47 (95% CI: 0.97, 2.23; P for trend = 0.032). We found an inverse association between stearic acid and the risk of total, localized, and low-grade prostate cancer; men in the highest quintile of stearic acid had a relative risk of 0.77 (95% CI: 0.56, 1.06; P for trend = 0.03). There were significant positive associations between myristic, alpha-linolenic, and eicosapentaenoic acids and risk of high-grade prostate cancer.
CONCLUSION: The associations between palmitic, stearic, myristic, alpha-linolenic, and eicosapentaenoic acids and prostate cancer risk may reflect differences in intake or metabolism of these fatty acids between the precancer cases and controls and should be explored further.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18996872     DOI: 10.3945/ajcn.2008.26369

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  60 in total

1.  Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Theodore M Brasky; Cathee Till; Emily White; Marian L Neuhouser; Xiaoling Song; Phyllis Goodman; Ian M Thompson; Irena B King; Demetrius Albanes; Alan R Kristal
Journal:  Am J Epidemiol       Date:  2011-04-24       Impact factor: 4.897

Review 2.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

3.  Changes in relative and absolute concentrations of plasma phospholipid fatty acids observed in a randomized trial of Omega-3 fatty acids supplementation in Uganda.

Authors:  Xiaoling Song; Pho Diep; Jeannette M Schenk; Corey Casper; Jackson Orem; Zeina Makhoul; Johanna W Lampe; Marian L Neuhouser
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2016-09-30       Impact factor: 4.006

4.  Blood fatty acid patterns are associated with prostate cancer risk in a prospective nested case-control study.

Authors:  Meng Yang; Azalea Ayuningtyas; Stacey A Kenfield; Howard D Sesso; Hannia Campos; Jing Ma; Meir J Stampfer; Jorge E Chavarro
Journal:  Cancer Causes Control       Date:  2016-08-03       Impact factor: 2.506

5.  Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial.

Authors:  Sarah H Nash; Jeannette M Schenk; Alan R Kristal; Phillis J Goodman; M Scott Lucia; Howard L Parnes; Ian M Thompson; Scott M Lippman; Xiaoling Song; Bora Gurel; Angelo De Marzo; Elizabeth A Platz
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-29

6.  Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study.

Authors:  Colleen Pelser; Alison M Mondul; Albert R Hollenbeck; Yikyung Park
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

7.  Myristoylation of Src kinase mediates Src-induced and high-fat diet-accelerated prostate tumor progression in mice.

Authors:  Sungjin Kim; Xiangkun Yang; Qianjin Li; Meng Wu; Leah Costyn; Zanna Beharry; Michael G Bartlett; Houjian Cai
Journal:  J Biol Chem       Date:  2017-09-22       Impact factor: 5.157

8.  Blood levels of saturated and monounsaturated fatty acids as markers of de novo lipogenesis and risk of prostate cancer.

Authors:  Jorge E Chavarro; Stacey A Kenfield; Meir J Stampfer; Massimo Loda; Hannia Campos; Howard D Sesso; Jing Ma
Journal:  Am J Epidemiol       Date:  2013-08-28       Impact factor: 4.897

9.  The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A meta-analysis.

Authors:  Michael E Chua; Maria Christina D Sio; Mishell C Sorongon; Marcelino L Morales
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

10.  Effect Modification by Time Since Blood Draw on the Association Between Circulating Fatty Acids and Prostate Cancer Risk.

Authors:  Meng Yang; Howard D Sesso; Graham A Colditz; Jing Ma; Meir J Stampfer; Jorge E Chavarro
Journal:  J Natl Cancer Inst       Date:  2016-06-13       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.